Affinity Asset Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Affinity Asset Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20,000	Closed	-$2.58M	–	70
2021 Q1	$2.58M	Buy	+20,000	New	+$3.04M	0.88%	32

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Affinity Asset Advisors's ASND Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Ascendis Pharma A/S (ASND) stake by 68% in Q2 2026, selling an estimated $15.2M and leaving 30,000 shares worth $8M. The position accounts for 0.36% of the portfolio, ranked #67.

Affinity Asset Advisors first reported a position in ASND in Q4 2020 and has held it in 15 quarters since. The position peaked at $21.7M in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Affinity Asset Advisors held 30,000 shares of Ascendis Pharma A/S worth $8M as of Q2 2026.
Affinity Asset Advisors sold 65,000 Ascendis Pharma A/S shares in Q2 2026, an estimated $15.2M.
Ascendis Pharma A/S made up 0.36% of Affinity Asset Advisors's portfolio in Q2 2026, its #67 holding.
Affinity Asset Advisors first reported a position in Ascendis Pharma A/S in Q4 2020 and has held it in 15 quarters since.
Affinity Asset Advisors's Ascendis Pharma A/S position peaked at $21.7M in Q1 2026.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.